No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
avecho.com.auNo one on the platform currently holds AVE.AX.
No tracked institution reports a position in AVE.AX as of their last filing.
No one on the platform has traded AVE.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 9.2% | 26.3% | ||||
| Profit Margin % | -356.8% | -399.2% | -482.0% | |||
| Free Cash Flow Margin % | 89.1% | -300.2% | -299.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3M | -78.1% | $-0.00 | $-0.00–$-0.00 | — | 1 |
| 2027 | $3M | -3.1% | $-0.00 | $-0.00–$-0.00 | — | 1 |
| 2028 | $9M | +187.1% | $0.00 | $0.00–$0.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| AVE.AXAvecho Biotechnology Limited | $0.02 | -4.76% | $77M | — |
| AGH.AXAlthea Group Holdings Limited | $0.02 | -4.76% | $17M | — |
| BTC.AXBTC Health Limited | $0.06 | +0.00% | $21M | — |
| ENL.AXEnlitic, Inc. | $0.04 | +5.71% | $3M | — |
| FRE.AXFirebrick Pharma Limited | $0.03 | +0.00% | $7M | — |
| IMC.AXImmuron Limited | $0.04 | -13.73% | $11M | — |
| MDR.AXMedAdvisor Limited | $0.02 | +0.00% | $14M | — |
Source: Financial Modeling Prep · peers by sector/industry